Atlas Trials

Shanghai Shengdi Pharmaceutical Co., Ltd

9 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Shanghai Shengdi Pharmaceutical Co., Ltd

RecordFirmDate
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer (NCT07522151)Shanghai Shengdi Pharmaceutical Co., Ltd2026-05-07
A Study of SHR-4610 Injection in Patients With Advanced Solid Tumors (NCT07231211)Shanghai Shengdi Pharmaceutical Co., Ltd2025-11-20
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Central Nervous System (CNS) Lesions (NCT07275814)Shanghai Shengdi Pharmaceutical Co., Ltd2025-11-17
A Study of a Gadolinium-Based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Body Parts (Non-Central Nervous System) Lesions (NCT07275723)Shanghai Shengdi Pharmaceutical Co., Ltd2025-11-14
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer (NCT07168200)Shanghai Shengdi Pharmaceutical Co., Ltd2025-10-17
Pharmacokinetics, Dialysability and Safety of HRS-9231 in Healthy Volunteers and in Patients With Impaired Renal Function (NCT06657560)Shanghai Shengdi Pharmaceutical Co., Ltd2024-10-14
Pharmacokinetics, Pharmacodynamics Profile and Tolerance of HRS-9231 in Healthy Subjects (NCT07123376)Shanghai Shengdi Pharmaceutical Co., Ltd2024-06-05
A Study of Chemoradiotherapy With SHR-1316 For Treatment of Locally Advanced Cervical Cancer (NCT06237257)Shanghai Shengdi Pharmaceutical Co., Ltd2024-03-20
A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients (NCT06335355)Shanghai Shengdi Pharmaceutical Co., Ltd2024-03-01

Track Shanghai Shengdi Pharmaceutical Co., Ltd automatically

Every clearance here is in the API, with alerts when new ones post.